Public health action needed to mitigate the impact of respiratory pathogens for 2023-24 winter season in Europe
In an epidemiological update, the ECDC urges EU/EEA Member States to strengthen vaccination campaigns and prepare for the possible need to increase emergency department and ICU capacity
Evaluation of the effectiveness and impact of Nirsevimab in Galicia
The NIRSE-GAL study shows in real time the evolution of the coverage achieved by immunisation with Nirsevimab in children and compares RSV admissions in different population groups of children and adults in Galicia in Spain with previous years.
First results in using new tools to tackle respiratory syncytial virus
Protecting infants from RSV with new tools: vaccines for pregnant women and use of monoclonal antibodies have been approved for use in the European Union to prevent RSV among young children. Are those tools working?
RSV IMMUNISATION FOR INFANTS IN EUROPE: ARE OUR HEALTH SYSTEMS READY?
EHMA publishes a paper based on expert insight from across Europe, exploring the challenges and opportunities of implementing RSV immunisation programmes in different country contexts.
Risk factors for severe respiratory syncytial virus infection during the first year of life: development and validation of a clinical prediction model
Novel immunisation methods against respiratory syncytial virus (RSV) are emerging, but knowledge of risk factors for severe RSV disease is insufficient for optimal targeting of interventions against them.
Risk factors for severe respiratory syncytial virus infection during the first year of life: development and validation of a clinical prediction model
Novel immunisation methods against respiratory syncytial virus (RSV) are emerging, but knowledge of risk factors for severe RSV disease is insufficient for optimal targeting of interventions against them.
The European Respiratory Virus Surveillance Summary (ERVISS)
This interactive dashboard provides a weekly integrated epidemiological summary for influenza, RSV and severe acute respiratory syndrome coronavirus 2 for the EU/EEA and the WHO European Region
WHO/Europe, EC and ECDC urge eligible groups to get vaccinated or boosted to save lives this autumn and winter
Last year’s autumn and winter seasons were unpredictable. Last winter, the cumulative impacts of influenza, COVID-19, and respiratory syncytial virus or RSV hit the very young and the very old the hardest.
|
9th Influenza Conference 2023
The Ninth ESWI Influenza Conference: Highlights
ESWI 2023: 10 key take home messages
Joint EMA-ECDC press briefing on current state of respiratory diseases and treatments in the EU/EEA
As autumn season approaches the EMA and ECDC held a press briefing to provide latest information on respiratory diseases as well as vaccines and treatments available
